UEEC: Well, the next major step is acquiring approval by the FDA for use of HemoStyp® as a hemostatic agent for use in surgical procedures. Once that occurs, which I believe to be all but a done deal due to the restructuring of United Health Products (UHP) executive leadership from a CEO who specializes in the medical field, who was utilized to shepherd the company's product through the complex clinical trials, to the new CEO who specializes in marketing pharmaceutical products.
The prior CEO, now remaining on the Board of Directors at UHP, is Douglas Beplate. Mr. Beplate served as UHP CEO from November 2014 to December 2020 and served as Chief Operating Officer starting November 2013. He became a director and Chairman of the Board in 2015. Mr. Beplate has supported the development of hemostatic technologies since 2003 and has been working on the development of HemoStyp gauze since 2010. From 1996 to 2007, Mr. Beplate was founder and President of Emergency Filtration Products, Inc. (“EFP”) where his responsibilities included product design, research and development, patent work and production. During his time at EFP, he was awarded a grant through California State University San Bernardino for development of nanotechnology for the U.S. government and military sector. Prior to his position at EFP he was a consultant to various medical products firms where he was involved in research and development, and product design.
The next steps, after receiving FDA approval, would be bifurcated into one of two options:
1. UHP ramping up internal production protocols for the commercialization of HemoStyp® by developing supply chain logistics for the manufacture and distribution of this clotting agent to take advantage of opportunities within the $5.8 billion global market demand; or, as a more likely scenario,
2. Due to its lack of capitalization, UHP would begin negotiations with a major pharmaceutical company with existent global production capabilities and distribution logistics to structure a buyout of the company at a fair market value given the PROVEN enhancements HemoStyp® would bring to the medical community. This most likely suitor for UHP would be Johnson and Johnson Pharmaceutical, the manufacturer of SURGICEL®, another hemostatic protocol and the most direct competitor for UHP's blood clotting treatment protocol.
Either of the aforementioned business propositions, in and of themself, involve complex legal, financial and business transactions and would be broken down into many steps in the process to coming to fruition.
While it is admittedly frustrating observing the share price of UEEC trade ostensibly sideways for the past three weeks, my suggestion is to STAY THE COURSE and disregard the current but TEMPORARY external forces currently roiling the markets as they will exert only a minimum impact on the share price of UEEC because the fundamentals of this company, as previously enumerated are too positive and so voluminous as to keep this stock trading below $5.00 per share for very long.